Ma XT, Yao GY, Li JL, Wang XC, Ba Y. Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report. World J Clin Oncol 2025; 16(11): 112029 [DOI: 10.5306/wjco.v16.i11.112029]
Corresponding Author of This Article
Yi Ba, Department of Cancer Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 41 Damucang Hutong, Xicheng District, Beijing 100032, China. bayi@pumch.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 24, 2025 (publication date) through Nov 21, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ma XT, Yao GY, Li JL, Wang XC, Ba Y. Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report. World J Clin Oncol 2025; 16(11): 112029 [DOI: 10.5306/wjco.v16.i11.112029]
World J Clin Oncol. Nov 24, 2025; 16(11): 112029 Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.112029
Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report
Xiao-Ting Ma, Guang-Yu Yao, Jian-Li Li, Xi-Cheng Wang, Yi Ba
Xiao-Ting Ma, Guang-Yu Yao, Xi-Cheng Wang, Yi Ba, Department of Cancer Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China
Jian-Li Li, Department of Medical Oncology, Changzhi Traditional Chinese Medicine Hospital, Changzhi 146000, Shanxi Province, China
Author contributions: Ma XT designed the article form and wrote the manuscript; Yao GY consulted and browsed the literature; Ma XT and Li JL collected and followed up patient information; Wang XC and Ba Y revised the manuscript; Ba Y provided funding support; all authors have read and approved the final manuscript.
Supported by CAMS Innovation Fund for Medical Sciences CIFMS, No. 2023-I2M-3-012.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Ba, Department of Cancer Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 41 Damucang Hutong, Xicheng District, Beijing 100032, China. bayi@pumch.cn
Received: July 16, 2025 Revised: August 23, 2025 Accepted: October 27, 2025 Published online: November 24, 2025 Processing time: 128 Days and 15.7 Hours
Abstract
BACKGROUND
Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) represents a distinct molecular cancer subtype that is often associated with a poor prognosis. While perioperative chemotherapy regimens are currently the primary recommendation for locally advanced HER2-positive GC, combination therapies incorporating immune checkpoint inhibitors are under active investigation.
CASE SUMMARY
The present case describes a patient with locally advanced HER2-positive GC who underwent perioperative treatment with chemotherapy combined with trastuzumab. Although significant tumor shrinkage was observed, surgical pathology results did not confirm the achievement of a pathological complete response. The current treatment strategies for advanced GC were also reviewed. Relevant case reports, retrospective studies, and prospective clinical trials were retrieved for analysis after searching the PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, and American Society of Clinical Oncology/European Society for Medical Oncology conference abstracts between 2014 and 2024.
CONCLUSION
Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.
Core Tip: The efficacy and safety of immune checkpoint inhibitors (ICIs) combination therapy in the perioperative period of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) have not been confirmed by large-scale clinical studies. This study introduces a case of neoadjuvant treatment for HER2-positive GC using standard chemotherapy combined with anti-HER2 therapy, and systematically summarizes the current related research on chemotherapy combined with targeted therapy and ICI-based combined therapy. The efficacy of ICI combined therapy during the perioperative period still requires further confirmation through a phase III clinical trial.
